Don’t cry manipulation when there is no non dilutive funds in connection with the combo trial. LP will be forced to dilute. So it’s all on LP.
They lied to shareholders in 2017 and this is going to run a similar fate. Let’s check again in Q1 2025.
JAMA has been out for over 2 years. Yet Specials revenue is abysmal. It won’t change much with the UK approval either without NICE reimbursement support. So the bleeding will continue for a couple of years! ;)
Market Data 
Markets 
AI
